Intellectual Property
The development work at Cyxone and the research performed by collaborating scientists continues to generate new patent opportunities for the company, and we regularly assess those opportunities.
In order to increase the commercial potential for Rabeximod and its attractiveness to potential partners, we are taking measures to expand its market exclusivity period. A number of additional patent applications have recently been filed, and we will continue exploring more options to further expand our IP platform.
Rabeximod Patents
| Patent name | Geographies | Expiration date |
|---|---|---|
| Alkyl substituted indoloquinoxalines | USA, UK, France, Spain, Germany, Sweden, India, China, Mexico, Japan | 2028 USA 2025 EU and other regions |
| Patent 2-5 (applied for) | TBD | 2041/ w PE 2043 |
T20K Patents
| Patent name | Geographies | Expiration date |
|---|---|---|
| Cyclotides as immunosuppressive agents* | USA, Europe, Canada, Australia | 2032 with +5yr PE |
* Patent owned by Medical University of Vienna